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GENERAL COMMENTS
The authors performed a study-level meta-analysis to determine the outcome of anticoagulated patients with intracranial hemorrhage exposed or not to anticoagulation resumption.
No data from clinical trials were available and therefore only (retrospectively conducted) cohort studies were included in the analysis. Main limitations to such approach have been already underlined by the reviewer who evaluated the manuscript in occasion of prior submission. Moreover, please note that at least 5 similar studies have been published in the past year/months: As commented in our recent letter published in Stroke (10.1161/STROKEAHA.117.018509), I believe that performing study-level meta-analysis in this setting does not provide better or additional evidence compared to the interpretation of large retrospective studies alone and, as also discussed by the authors, does not improve/change clinical practice.
Major comments: -study-level meta-analysis does not permit to adjust for relevant covariates (i.e. site of intracranial bleeding, comorbidities, delay of anticoagulant resumption); -confounding by indication has a large impact on risk estimates; -study populations are heterogeneous (AFib, VTE, mechanical heart valves), as well outcomes (recurrent ischemic stroke, recurrent VTE, valve thrombosis); -one cannot exclude a major role of death as a competing risk for other clinical outcomes; -pooled incidence rate ratios should also be provided since different studies adopted various follow-up lengths.
address an important topic, of clinical relevance for a broad range of clinicians, particularly cardiologists, neurologist, and primary care doctors.
Overall this is a detailed review, with useful supplementary material with the tables and subsequent analyses performed. The methods are adequately reported, in a way that are reproducible and followed standardized guidelines for reporting. PRISMA was followed, and the study was registered in PROSPERO (date of registration was April 2017, date of initiation of research activities was February 2016).
The authors appropriately used random effects for their metaanalyses. Random effects account for the clinical and statistical heterogeneity between studies, and calculate a more conservative confidence interval. The effects of treatment are assumed to vary around some overall average treatment effect, as opposed to a fixed-effects model, in which it is assumed that each study has the same fixed common treatment effect. Most the included studies had a retrospective design and have heterogeneity in treatment regimens and timing of anticoagulation restart. There are likely many unmeasured confounders that warrant caution with the interpretation. Adding these observational studies together in a meta-analysis and providing pooled estimates by study-level meta-analysis would not minimize such risk, meaning that the meta-analysis is only as good as the quality of the body of evidence placed into it. Also it is very likely that the clinicians decision to restart anticoagulation was referred in some patients compared to other depending on their risk benefit of bleeding vs thromboembolic disease. Currently this systematic review is of limited utility for clinicians, as many questions remain unanswered. Most of the limitations are limitations of the data available itself, and not the development of the systematic review. As clinicians we know that the risks of being off anticoagulation for a patient with a mechanical valve is higher than someone with a provoked DVT. Data that might help to orient clinicians and patients is type of bleed (intraparecnhymal, subdural, etc), location of bleed (lobar versus other), cardiovascular risk/indication for anticoagulation (ie: atrial fibrillation, mechanical valve, venous thromboembolism), and risk benefit of the anticoagulation , ie: ischemic disease, GI bleed. The authors addressed most of these issues including location of bleed in Table 2 , however there are multiple binary comparisons with variable heterogeneity that limit its applicability.
The question on when to initiate anticoagulation (timing) still remains unknown.
In the discussion section, the authors should be more cautious when using composite outcomes as main outcome. The discussion currently starts as "This systematic review and meta-analysis showed that resuming anticoagulant therapy after interruption for anticoagulation-associated ICH reduced the risks of thromboembolic events and thromboembolic events plus recurrent ICH, without significantly increasing the risks of ICH recurrence and long-term mortality." However the results report: "There was no significant association of resuming anticoagulant therapy with either long-term mortality (pooled RR 0.60, 95% CI 0.30 to 1.19; p=0.14) or ICH recurrence (pooled RR 1.14, 95% CI 0.72 to 1.80; p=0.57) ( Fig. 2 and Table S4 ). There were significant associations of resuming anticoagulant therapy with lower risks of thromboembolic events (pooled RR 0.31, 95% CI 0.23 to 0.42; p<0.001) or thromboembolic events plus recurrent ICH (pooled RR 0.53, 95% CI 0.42 to 0.66; p<0.001)"
Composite outcomes mask individual outcome results, are difficult to interpret by patients and clinician, and raise the questions about the minimum clinically important difference. In this case there was no difference in ICH recurrence when analyzed as a single outcome, but appears as "beneficial" for ICH recurrence when presented as composite outcome including thromboembolism plus ICH recurrence. Determining the minimum clinically important difference for a composite outcome is difficult, because even if the occurrence and importance of individual components is known, the overall occurrence and importance of the composite outcome is very difficult to estimate. Evidence should also be sought from clinicians about the size of difference that would change their behavior, but it may be difficult for them to make an estimate based on an outcome composed of a number of heterogeneous items. ) have been published in the past 10 months, and we would like to declare that our work started before these three papers being published. It is not uncommon that different groups conduct the systematic review on the same topic at the same time. Although the first published paper has influence on the originality of later published papers, attentions from more researchers may reflect the urgent need to advance knowledge on this topic. There are still differences among our study and three published papers in included studies, included participants and primary outcomes: (1) the outcome of mortality is not analyzed in Murthy et al and Korompoki et al, it is analyzed in Chai-Adisaksopha C et al and our study; (2) all-cause mortality is pooled in ChaiAdisaksopha C et al and long-term mortality after excluding mortality at the acute phase or hospitalization is pooled in our study; (3) participants receiving antiplatelet agents after ICH are taken into consideration in Korompoki et al and our study, they are not included in Murthy et al and ChaiAdisaksopha C et al; (4) AF participants are only focused on in Korompoki et al, participants with various indications of anticoagulation are analyzed in our study and other two published papers. We hope our paper being published, which is a good way to present our work and communicate with peers on this hot topic.
2. The present study shows no difference in mortality between the AC and no-AC groups. However, a very recent prospective study from Biffi et al. (Annals of Neurology, 2017) using data from US and Europe shows that resumption of AC therapy was associated with a significantly lower mortality and improved functional outcomes, regardless of the location of the hemorrhage. Could the authors clarify on the discrepancy in the results?
Response: Biffi et al reported that resuming anticoagulant after ICH was associated with the decrease of 1-year mortality and long-term mortality in participants with nonvalvular AF based on meta-analysis of individual patient data, regardless of hematoma location. Chai-Adisaksopha C et al also reported same pooling result based on study-level meta-analysis. There are several reasons why our result on long-term mortality is different from Biffi et al and Chai-Adisaksopha C et al: (1) participants who switched to antiplatelet agents after ICH are not included as comparator in Biffi et al and ChaiAdisaksopha C et al, but are included in our meta-analysis (see comparator(s)/control section of the registered protocol [PROSPERO CRD42017063827] and methods-eligibility criteria section of the paper); (2) most of the included studies recruited participants with various indications of anticoagulation and the follow-up length is different among studies, which may induce potential difference between our result and Biffi et al's; (3) for one included study (Yung et al. 2012; 28(1) :33-9), the method of data extraction is different in our study and in Chai-Adisaksopha C et al. According to the table 3 of Yung et al, in-hospital death for warfarin restarted and not restarted are 30 and 98, and 1 year death are 44 and 118, respectively. We excluded the death in hospital in our study to avoid the bias caused by the acute phase. The death after discharging from hospital (14 for warfarin restarted and 20 for not restarted) are used for meta-analysis in this study.
We have added a subgroup analysis based on two included studies (Kuramatsu et al JAMA. 2015; 313(8) and Nielsen et al Circulation. 2015; 132(6) ) with AF participants. The result ( Figure S2 ) is consistent to Biffi et al's.
Reviewer 2 This is a well written meta analysis. It appears that the authors have satisfactorily responded to the major issues raised in an earlier peer review that was included along with this submission. The writing is clear and concise. The conclusions are reasonable given the summarized evidence. The methodology seems appropriate. This work is confirmatory to similar meta analyses.
Response: Thanks for the comment.
Reviewer 3 1. No data from clinical trials were available and therefore only (retrospectively conducted) cohort studies were included in the analysis. Main limitations to such approach have been already underlined by the reviewer who evaluated the manuscript in occasion of prior submission. Moreover, please note that at least 5 similar studies have been published in the past year/months. As commented in our recent letter published in Stroke (10.1161/STROKEAHA.117.018509), I believe that performing studylevel meta-analysis in this setting does not provide better or additional evidence compared to the interpretation of large retrospective studies alone and, as also discussed by the authors, does not improve/change clinical practice.
Response: See response to Reviewer 1-1.
2. Study-level meta-analysis does not permit to adjust for relevant covariates (i.e. site of intracranial bleeding, comorbidities, delay of anticoagulant resumption).
Response: We have specified this issue in the discussion section.
6. Pooled incidence rate ratios should also be provided since different studies adopted various followup lengths.
Response: Pooled incidence rate ratios cannot be calculated because the exact length of follow-up (patient-years) cannot be extracted in some included studies. Instead, we performed a metaregression to show the effect of follow-up length on long-term mortality and ICH recurrence.
Reviewer 4 1. The authors used funnel plots, as a caution note, funnel plots can be misleading when less than 10 studies are evaluated. [reference Lau J, et al. BMJ. 2006 Sep 16; 333(7568):597-600.] . The risk of bias and quality was assessed by the authors.
Response: We agree that funnel plots are more appropriate to be applied when more than 10 studies being included in the meta-analysis although actually they are used for analysis of publication bias in part of the published meta-analysis in which less than 10 studies are evaluated. We added a specification on this issue in the discussion-limitation section.
2. Unfortunately a very similar systematic review was published on the same topic, and the authors address their differences in the discussion, however it brings into question for the journal editors the value of publishing a second very similar review. Response: See response to Reviewer 1-1.
3. Most the included studies had a retrospective design and have heterogeneity in treatment regimens and timing of anticoagulation restart. There are likely many unmeasured confounders that warrant caution with the interpretation. Adding these observational studies together in a meta-analysis and providing pooled estimates by study-level meta-analysis would not minimize such risk, meaning that the meta-analysis is only as good as the quality of the body of evidence placed into it. Also it is very likely that the clinicians decision to restart anticoagulation was referred in some patients compared to other depending on their risk benefit of bleeding vs thromboembolic disease. Currently this systematic review is of limited utility for clinicians, as many questions remain unanswered. Most of the limitations are limitations of the data available itself, and not the development of the systematic review.
Response: In this study, we aim to provide an updated systematic review and meta-analysis on the risks of adverse outcomes following resumption of anticoagulation in patients who experience anticoagulation-associated ICH and survive the acute phase or hospitalization through rigorous method and comprehensive literature search. The quality of the meta-analysis depends on the quality of current evidence, by which it is far too soon to form management recommendations or improve clinical practice because of many unmeasured confounders in existing observational studies. We note that a divergence in the results obtained from earlier observational studies and randomized controlled trials has been frequently described, and call for the RCT-based evidence in the conclusion section.
4. As clinicians we know that the risks of being off anticoagulation for a patient with a mechanical valve is higher than someone with a provoked DVT. Data that might help to orient clinicians and patients is type of bleed (intraparecnhymal, subdural, etc), location of bleed (lobar versus other), cardiovascular risk/indication for anticoagulation (ie: atrial fibrillation, mechanical valve, venous thromboembolism), and risk benefit of the anticoagulation , ie: ischemic disease, GI bleed. The authors addressed most of these issues including location of bleed in Table 2 , however there are multiple binary comparisons with variable heterogeneity that limit its applicability.
Response: We added a clarification on this issue in the discussion-limitation section.
5. The question on when to initiate anticoagulation (timing) still remains unknown.
Response: On this issue, we think further research stratified by anticoagulation indication and other confounding factors should advance knowledge.
6. In the discussion section, the authors should be more cautious when using composite outcomes as main outcome. The discussion currently starts as "This systematic review and meta-analysis showed that resuming anticoagulant therapy after interruption for anticoagulation-associated ICH reduced the risks of thromboembolic events and thromboembolic events plus recurrent ICH, without significantly increasing the risks of ICH recurrence and long-term mortality." However the results report: "There was no significant association of resuming anticoagulant therapy with either long-term mortality (pooled RR 0.60, 95% CI 0.30 to 1.19; p=0.14) or ICH recurrence (pooled RR 1.14, 95% CI 0.72 to 1.80; p=0.57) ( Fig. 2 and Table S4 ). There were significant associations of resuming anticoagulant therapy with lower risks of thromboembolic events (pooled RR 0.31, 95% CI 0.23 to 0.42; p<0.001) or thromboembolic events plus recurrent ICH (pooled RR 0.53, 95% CI 0.42 to 0.66; p<0.001)".
Response: We removed composite outcomes as suggested and corresponding revisions have been made in the result and discussion section.
7. Composite outcomes mask individual outcome results, are difficult to interpret by patients and clinician, and raise the questions about the minimum clinically important difference. In this case there was no difference in ICH recurrence when analyzed as a single outcome, but appears as "beneficial" for ICH recurrence when presented as composite outcome including thromboembolism plus ICH recurrence. Determining the minimum clinically important difference for a composite outcome is difficult, because even if the occurrence and importance of individual components is known, the overall occurrence and importance of the composite outcome is very difficult to estimate. Evidence should also be sought from clinicians about the size of difference that would change their behavior, but it may be difficult for them to make an estimate based on an outcome composed of a number of heterogeneous items. [Reference: Ross, S. Composite outcomes in randomized clinical trials: arguments for and against. https://doi.org/10.1016/j.ajog.2006.10.903). Composite outcomes may reduce the credibility of the research, and may impact on the implementation of findings. I suggest you do not combine the outcomes as currently stated in the manuscript, particularly because based on figure 2, ICH tends to favor no reinitiation of AC and TEE goes in the opposite direction.
Response: We agree that composite outcomes may potentially induce incorrect interpretation of the minimum clinically important difference since masking individual outcome results. We removed the composite outcomes as suggested.
